http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 12 Feb 2025 08:32:39 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Tivic+Health+Systems+%28TIVC%29+acquires+rights+to+Entolimod+from+Statera+Biopharma/24332953.html <p>Tivic Health Systems, Inc., (Nasdaq: TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC: STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement establishes Tivic as a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline.</p><p>“Today, we have aggressively accelerated Tivic’s strategic transformation from a single-product, direct-to-consumer company to a diversified therapeutics company—one http://www.streetinsider.com/Corporate+News/Tivic+Health+Systems+%28TIVC%29+acquires+rights+to+Entolimod+from+Statera+Biopharma/24332953.html Wed, 12 Feb 2025 08:32:39 -0400 STAB TIVC http://www.streetinsider.com/Corporate+News/Tivic+Health+Systems+%28TIVC%29+acquires+rights+to+Entolimod+from+Statera+Biopharma/24332953.html <p>Tivic Health Systems, Inc., (Nasdaq: TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC: STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement establishes Tivic as a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline.</p><p>“Today, we have aggressively accelerated Tivic’s strategic transformation from a single-product, direct-to-consumer company to a diversified therapeutics company—one http://www.streetinsider.com/Corporate+News/Tivic+Health+Systems+%28TIVC%29+acquires+rights+to+Entolimod+from+Statera+Biopharma/24332953.html Wed, 12 Feb 2025 08:32:39 -0400 STAB TIVC http://www.streetinsider.com/Press+Releases/Tivic+Health+Acquires+Exclusive+Worldwide+Rights+to+Phase+III+TLR5+Agonist+from+Statera+Biopharma/24332896.html <p class="bwalignc"> <i>Broad licensing agreement accelerates Tivic’s transformation into a diversified therapeutics company, adds late-stage immunotherapeutic to clinical pipeline. Potential for FDA approval within 24 months.</i> </p> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health Systems, Inc., (Nasdaq: TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC: STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement establishes Tivic as a diversified http://www.streetinsider.com/Press+Releases/Tivic+Health+Acquires+Exclusive+Worldwide+Rights+to+Phase+III+TLR5+Agonist+from+Statera+Biopharma/24332896.html Wed, 12 Feb 2025 08:30:00 -0400 O.01521575 O.52936745 STAB TIVC http://www.streetinsider.com/Press+Releases/Tivic+Health+Acquires+Exclusive+Worldwide+Rights+to+Phase+III+TLR5+Agonist+from+Statera+Biopharma/24332896.html <p class="bwalignc"> <i>Broad licensing agreement accelerates Tivic’s transformation into a diversified therapeutics company, adds late-stage immunotherapeutic to clinical pipeline. Potential for FDA approval within 24 months.</i> </p> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health Systems, Inc., (Nasdaq: TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC: STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement establishes Tivic as a diversified http://www.streetinsider.com/Press+Releases/Tivic+Health+Acquires+Exclusive+Worldwide+Rights+to+Phase+III+TLR5+Agonist+from+Statera+Biopharma/24332896.html Wed, 12 Feb 2025 08:30:00 -0400 O.01521575 O.52936745 STAB TIVC http://www.streetinsider.com/Press+Releases/Tivic+Health+Acquires+Exclusive+Worldwide+Rights+to+Phase+III+TLR5+Agonist+from+Statera+Biopharma/24332896.html <p class="bwalignc"> <i>Broad licensing agreement accelerates Tivic’s transformation into a diversified therapeutics company, adds late-stage immunotherapeutic to clinical pipeline. Potential for FDA approval within 24 months.</i> </p> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health Systems, Inc., (Nasdaq: TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC: STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement establishes Tivic as a diversified http://www.streetinsider.com/Press+Releases/Tivic+Health+Acquires+Exclusive+Worldwide+Rights+to+Phase+III+TLR5+Agonist+from+Statera+Biopharma/24332896.html Wed, 12 Feb 2025 08:30:00 -0400 O.01521575 O.52936745 STAB TIVC http://www.streetinsider.com/Press+Releases/Tivic+Health+Acquires+Exclusive+Worldwide+Rights+to+Phase+III+TLR5+Agonist+from+Statera+Biopharma/24332896.html <p class="bwalignc"> <i>Broad licensing agreement accelerates Tivic’s transformation into a diversified therapeutics company, adds late-stage immunotherapeutic to clinical pipeline. Potential for FDA approval within 24 months.</i> </p> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health Systems, Inc., (Nasdaq: TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC: STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement establishes Tivic as a diversified http://www.streetinsider.com/Press+Releases/Tivic+Health+Acquires+Exclusive+Worldwide+Rights+to+Phase+III+TLR5+Agonist+from+Statera+Biopharma/24332896.html Wed, 12 Feb 2025 08:30:00 -0400 O.01521575 O.52936745 STAB TIVC http://www.streetinsider.com/Business+Wire/Tivic+Health+Acquires+Exclusive+Worldwide+Rights+to+Phase+III+TLR5+Agonist+from+Statera+Biopharma/24332896.html <p class="bwalignc"> <i>Broad licensing agreement accelerates Tivic’s transformation into a diversified therapeutics company, adds late-stage immunotherapeutic to clinical pipeline. Potential for FDA approval within 24 months.</i> </p> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health Systems, Inc., (Nasdaq: TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC: STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement establishes Tivic as a diversified http://www.streetinsider.com/Business+Wire/Tivic+Health+Acquires+Exclusive+Worldwide+Rights+to+Phase+III+TLR5+Agonist+from+Statera+Biopharma/24332896.html Wed, 12 Feb 2025 08:30:00 -0400 O.01521575 O.52936745 STAB TIVC http://www.streetinsider.com/Business+Wire/Tivic+Health+Acquires+Exclusive+Worldwide+Rights+to+Phase+III+TLR5+Agonist+from+Statera+Biopharma/24332896.html <p class="bwalignc"> <i>Broad licensing agreement accelerates Tivic’s transformation into a diversified therapeutics company, adds late-stage immunotherapeutic to clinical pipeline. Potential for FDA approval within 24 months.</i> </p> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health Systems, Inc., (Nasdaq: TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC: STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement establishes Tivic as a diversified http://www.streetinsider.com/Business+Wire/Tivic+Health+Acquires+Exclusive+Worldwide+Rights+to+Phase+III+TLR5+Agonist+from+Statera+Biopharma/24332896.html Wed, 12 Feb 2025 08:30:00 -0400 O.01521575 O.52936745 STAB TIVC http://www.streetinsider.com/Business+Wire/Tivic+Health+Acquires+Exclusive+Worldwide+Rights+to+Phase+III+TLR5+Agonist+from+Statera+Biopharma/24332896.html <p class="bwalignc"> <i>Broad licensing agreement accelerates Tivic’s transformation into a diversified therapeutics company, adds late-stage immunotherapeutic to clinical pipeline. Potential for FDA approval within 24 months.</i> </p> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health Systems, Inc., (Nasdaq: TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC: STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement establishes Tivic as a diversified http://www.streetinsider.com/Business+Wire/Tivic+Health+Acquires+Exclusive+Worldwide+Rights+to+Phase+III+TLR5+Agonist+from+Statera+Biopharma/24332896.html Wed, 12 Feb 2025 08:30:00 -0400 O.01521575 O.52936745 STAB TIVC http://www.streetinsider.com/Business+Wire/Tivic+Health+Acquires+Exclusive+Worldwide+Rights+to+Phase+III+TLR5+Agonist+from+Statera+Biopharma/24332896.html <p class="bwalignc"> <i>Broad licensing agreement accelerates Tivic’s transformation into a diversified therapeutics company, adds late-stage immunotherapeutic to clinical pipeline. Potential for FDA approval within 24 months.</i> </p> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health Systems, Inc., (Nasdaq: TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC: STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement establishes Tivic as a diversified http://www.streetinsider.com/Business+Wire/Tivic+Health+Acquires+Exclusive+Worldwide+Rights+to+Phase+III+TLR5+Agonist+from+Statera+Biopharma/24332896.html Wed, 12 Feb 2025 08:30:00 -0400 O.01521575 O.52936745 STAB TIVC